|
Volumn 111, Issue 8, 2001, Pages 667-668
|
Is it time for mass screening for hepatitis C?
a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
ANTIVIRUS AGENT;
ILLICIT DRUG;
MACROGOL;
RECOMBINANT ALPHA INTERFERON;
RIBAVIRIN;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
BLOOD TRANSFUSION;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG ABUSE;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
EDITORIAL;
FOLLOW UP;
GENOTYPE;
HEALTH CARE POLICY;
HEPATITIS C;
HEPATITIS C VIRUS;
HIGH RISK POPULATION;
HUMAN;
INCIDENCE;
LIVER CELL CARCINOMA;
LIVER CIRRHOSIS;
MASS SCREENING;
MEDICAL ASSESSMENT;
MORBIDITY;
MORTALITY;
PATIENT COUNSELING;
PRIORITY JOURNAL;
PUBLIC HEALTH;
RISK FACTOR;
VIRUS TRANSMISSION;
HEPATITIS C;
HUMANS;
INCIDENCE;
MASS SCREENING;
PREVALENCE;
UNITED STATES;
|
EID: 0035704048
PISSN: 00029343
EISSN: None
Source Type: Journal
DOI: 10.1016/S0002-9343(01)01045-2 Document Type: Editorial |
Times cited : (1)
|
References (17)
|